Glenzocimab (ACT017)
Acute Ischemic Stroke
Key Facts
About Acticor Biotech
Acticor Biotech is advancing a targeted therapeutic platform focused on inhibiting platelet glycoprotein VI (GPVI) to treat acute thrombotic diseases with a potentially superior safety profile. Its lead asset, glenzocimab, has demonstrated promising Phase 1b/2a results in acute ischemic stroke (AIS) and is progressing into a pivotal Phase 2/3 study (ACTISAVE), alongside a Phase 2 program in myocardial infarction. The company's strategy is to establish glenzocimab as a new standard of care adjuvant therapy, used alongside thrombolysis and thrombectomy, to improve recanalization and functional outcomes while minimizing bleeding risk.
View full company profileAbout Acticor Biotech
Acticor Biotech is advancing a targeted therapeutic platform focused on inhibiting platelet glycoprotein VI (GPVI) to treat acute thrombotic diseases with a potentially superior safety profile. Its lead asset, glenzocimab, has demonstrated promising Phase 1b/2a results in acute ischemic stroke (AIS) and is progressing into a pivotal Phase 2/3 study (ACTISAVE), alongside a Phase 2 program in myocardial infarction. The company's strategy is to establish glenzocimab as a new standard of care adjuvant therapy, used alongside thrombolysis and thrombectomy, to improve recanalization and functional outcomes while minimizing bleeding risk.
View full company profileTherapeutic Areas
Other Acute Ischemic Stroke Drugs
| Drug | Company | Phase |
|---|---|---|
| AST-004 | Astrocyte Pharmaceuticals | Phase 1/2 |
| scp776 | Silver Creek Pharmaceuticals | Phase 2 |
| VB-001 | VST Bio | Pre-clinical |
| Pulse NanoMED for AIS | Euphrates Vascular | Pre-clinical |
| NeVa NET | Vesalio | Development/Commercial |
| ApTOLL | aptaTargets | Phase 2 |
| ThermoSuit® for Acute Ischemic Stroke | Life Recovery Systems HD | Pivotal Trial (Planned) |
| Pulsante for Ischemic Stroke | Realeve | Research/Clinical Study |